EICHOR
● Active Not Recruiting
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
Condition: Relapsed Multiple Myeloma · Sponsor: PETHEMA Foundation
About this study
This is a phase I-II open-label, multicenter, non-randomized study aiming to evaluate the efficacy and safety of belantamab mafodotin in combination with carfilzomib (Kyprolis®) and dexamethasone (Kd). Since this is the first time that this combination is being evaluated in a clinical trial, a first dose escalation part will be developed following the classic 3+3 design, to establish the maximum tolerated dose (MTD) of the combination. Once the MTD will be defined, a dose expansion phase will be open to recruit up to 60 patients. Patients will receive treatment with belantamab-mafodotin + Kd, until unacceptable toxicity, disease progression, patient withdrawal, loss to follow-up, end of study, or death.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (15)
| Hospital Germans Trias i Pujol (ICO BADALONA) | Badalona, Spain | — |
| Hospital Clinic | Barcelona, Spain | — |
| ICO Duran i Reynals | L'Hospitalet de Llobregat, Spain | — |
| H. Gregorio Marañón | Madrid, Spain | — |
| Hospital Universitario 12 de Octubre | Madrid, Spain | — |
| H. Morales Meseguer | Murcia, Spain | — |
| HUCA | Oviedo, Spain | — |
| H. Son Llatzer | Palma de Mallorca, Spain | — |
| Clínica Universidad de Navarra (CUN) | Pamplona, Spain | — |
| Hospital Universitario de Salamanca | Salamanca, Spain | — |
| H. Universitario de Canarias | Santa Cruz de Tenerife, Spain | — |
| H. Universitario Marqués de Valdecilla | Santander, Spain | — |
+ 3 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05060627